Financial reports
10-Q
2024 Q2
Quarterly report
24 Apr 24
10-Q
2024 Q1
Quarterly report
19 Jan 24
10-K
2023 FY
Annual report
20 Nov 23
10-Q
2023 Q3
Quarterly report
25 Jul 23
10-Q
2023 Q2
Quarterly report
18 Apr 23
10-Q
2023 Q1
Quarterly report
19 Jan 23
10-K
2022 FY
Annual report
15 Nov 22
10-Q
2022 Q3
Quarterly report
22 Jul 22
10-Q
2022 Q2
Quarterly report
21 Apr 22
10-Q
2022 Q1
Quarterly report
20 Jan 22
Current reports
8-K
Other Events
9 Feb 24
8-K
Entry into a Material Definitive Agreement
18 Sep 23
8-K
Unregistered Sales of Equity Securities
21 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Feb 23
8-K
Unregistered Sales of Equity Securities
21 Nov 22
8-K
Unregistered Sales of Equity Securities
18 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
14 Nov 22
8-K
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
20 Sep 22
8-K
Other Events
10 Aug 22
8-K
Unregistered Sales of Equity Securities
20 Jul 22
Registration and prospectus
424B3
Prospectus supplement
24 Apr 24
424B3
Prospectus supplement
9 Feb 24
424B3
Prospectus supplement
19 Jan 24
424B3
Prospectus supplement
20 Nov 23
424B3
Prospectus supplement
2 Oct 23
S-1
IPO registration
25 Sep 23
RW
Registration withdrawal request
24 Jul 23
424B3
Prospectus supplement
15 May 23
S-1/A
IPO registration (amended)
2 May 23
S-1
IPO registration
13 Apr 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
27 Sep 23
UPLOAD
Letter from SEC
27 Sep 23
EFFECT
Notice of effectiveness
15 May 23
CORRESP
Correspondence with SEC
11 May 23
CORRESP
Correspondence with SEC
2 May 23
UPLOAD
Letter from SEC
27 Apr 23
UPLOAD
Letter from SEC
2 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
30 Mar 17